AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31039409 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) followed by allogeneic HSCT in first-HSCT patients (n=86)
Number of subjects: 101
Study 31039409 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) followed by allogeneic HSCT in patients who went directly to first HSCT upon remission (n=73)
Number of subjects: 101
Study 31039789 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of insulin resistance (measured by HOMA-IR)
Number of subjects: 3128
Study 31039789 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing quartiles of HOMA-IR
Number of subjects: 3128
Study 31039807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous abatacept (weight-tiered: <75 kg: 10 mg/kg; 75-100 kg: 750 mg; >100 kg: 1000 mg) administered at Weeks 0, 2, 4, and every 4 weeks thereafter for 16 weeks.
Number of subjects: 20
Study 31039807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous abatacept
Number of subjects: 20
Study 31040126 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF-A/ANG-2 neutralization
Number of subjects: 0
Study 31040256 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-TKI (erlotinib 150 mg or gefitinib 250 mg per day) plus thoracic radiotherapy (54-60 Gy/27-30 F/5.5-6 w)
Number of subjects: 10
Study 31040791 — intervention group
Group type: EXPERIMENTAL
Intervention: -12° Head Down Tilt (HDT) for 21 hours
Number of subjects: 11
Study 31040791 — intervention group
Group type: COMPARATOR
Intervention: Horizontal position for 21 hours
Number of subjects: 11
Study 31041522 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella locking plate fixation
Number of subjects: 20
Study 31042149 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging, theory-driven newsletters, and behavioral coaching for changing sedentary behavior.
Number of subjects: 0
Study 31042669 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg subcutaneously twice-daily)
Number of subjects: 67
Study 31042669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 31042684 — intervention group
Group type: EXPERIMENTAL
Intervention: SpikeDeeptector algorithm
Number of subjects: 7
Study 31042825 — intervention group
Group type: EXPERIMENTAL
Intervention: bb2121 CAR T-cell therapy
Number of subjects: 33
Study 31043157 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy (WBVT) - 20 Hz, 2 mm amplitude, 3 bouts of 3 minutes, 4 days per week for 4 weeks.
Number of subjects: 14
Study 31043157 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration therapy (WBVT)
Number of subjects: 14
Study 31043390 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vitamin D (1,000 IU/day)
Number of subjects: 3
Study 31043390 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (5,000 IU/day)
Number of subjects: 3
Study 31043390 — intervention group
Group type: COMPARATOR
Intervention: Control (without vitamin D)
Number of subjects: 3
Study 31043539 — intervention group
Group type: EXPERIMENTAL
Intervention: DISH present
Number of subjects: 1784
Study 31043539 — intervention group
Group type: COMPARATOR
Intervention: DISH absent
Number of subjects: 1784
Study 31044001 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver Qi Stagnation (LQS)
Number of subjects: 44
Study 31044001 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart and Spleen Deficiency (HSD)
Number of subjects: 44
Study 31044001 — intervention group
Group type: EXPERIMENTAL
Intervention: Insular connectivity
Number of subjects: 44
Study 31044307 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy (RT)
Number of subjects: 55
Study 31044328 — intervention group
Group type: EXPERIMENTAL
Intervention: Right coronary artery (RCA) motion analysis during selective coronary angiography
Number of subjects: 97
Study 31044328 — intervention group
Group type: EXPERIMENTAL
Intervention: Right coronary artery (RCA) maximum speed during selective coronary angiography
Number of subjects: 97
Study 31044414 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anemia
Number of subjects: 851
Study 31044728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsupine positioning after pars plana vitrectomy with internal limiting membrane peeling and sulfur hexafluoride gas tamponade for 3 to 5 days.
Number of subjects: 203
Study 31044728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsupine positioning
Number of subjects: 203
Study 31045222 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose intradermal influenza vaccine
Number of subjects: 158
Study 31045797 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for hepatitis B virus (HBV) using HBsAg, anti-HBs, and anti-HBc tests after educational meetings, at the Outpatient Hepatology Department, and home visits.
Number of subjects: 0
Study 31045797 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational meetings concerning viral hepatitis B.
Number of subjects: 0
Study 31045797 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment of HBsAg-positive patients six months after screening.
Number of subjects: 0
Study 31045797 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire regarding sociodemographic factors, migration history, risk factors for HBV infection, and vaccination status.
Number of subjects: 0
Study 31045955 — intervention group
Group type: EXPERIMENTAL
Intervention: Designated code team and hospital-wide code team activation system
Number of subjects: 18
Study 31045955 — intervention group
Group type: EXPERIMENTAL
Intervention: Preassigned roles for code team members
Number of subjects: 18
Study 31045955 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of step stool and backboard during resuscitations
Number of subjects: 18
Study 31045955 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of CPR feedback
Number of subjects: 18
Study 31045955 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual feedback device incorporated into the defibrillator
Number of subjects: 18
Study 31045955 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of CPR coach
Number of subjects: 18
Study 31045955 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary and simulation-based code team training
Number of subjects: 18
Study 31046124 — intervention group
Group type: EXPERIMENTAL
Intervention: Total circulating cell-free DNA (cfDNA) levels above upper limit of normal (ULN)
Number of subjects: 493
Study 31046124 — intervention group
Group type: EXPERIMENTAL
Intervention: Total circulating cell-free DNA (cfDNA) levels below upper limit of normal (ULN)
Number of subjects: 493
Study 31046124 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA levels predicted by tumor burden and inflammatory response
Number of subjects: 493
Study 31046586 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Memory Notebook (DMN) application intervention
Number of subjects: 3
Study 31046714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg q3w i.v. for 2 cycles)
Number of subjects: 30
Study 31046720 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity on Prescription (PAP) treatment including individual counseling, tailored PA recommendation, written prescription, and structured follow-up for 6 months
Number of subjects: 444
Study 31046720 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity on Prescription (PAP) treatment
Number of subjects: 444
Study 31046730 — intervention group
Group type: EXPERIMENTAL
Intervention: Novosyn® Quick
Number of subjects: 100
Study 31046729 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirdhand smoke (THS) exposure in homes of smokers who smoke indoors, have smoking bans, or have quit smoking.
Number of subjects: 0
Study 31046729 — intervention group
Group type: COMPARATOR
Intervention: Secondhand smoke (SHS) exposure in homes of smokers who smoke indoors, have smoking bans, or have quit smoking.
Number of subjects: 0
Study 31046729 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical analyses of home dust samples for THS pollutants.
Number of subjects: 0
Study 31046729 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic medical record review of child respiratory illness.
Number of subjects: 0
Study 31046743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every third week in combination with entinostat 5 mg orally once weekly.
Number of subjects: 29
Study 31046743 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 29
Study 31046764 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired pneumonia (CAP)
Number of subjects: 52
Study 31046764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis of lipid profiles in CAP patients
Number of subjects: 52
Study 31046764 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific lipid profiles in CAP
Number of subjects: 52
Study 31046764 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day mortality in CAP clusters
Number of subjects: 52
Study 31046839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral treatment with BO-112
Number of subjects: 0
Study 31046839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral treatment with BO-112 plus systemic anti-CD137 and anti-PD-L1 mAbs
Number of subjects: 0
Study 31047001 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL apolipoproteomic score (pCAD)
Number of subjects: 943
Study 31047111 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study 31047111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31047115 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) delivered by breath-actuated inhaler (BAI)
Number of subjects: 0
Study 31047115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31047503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 746
Study 31047503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 746
Study 31047503 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 746
Study 31047955 — intervention group
Group type: EXPERIMENTAL
Intervention: SGRQ CB definition
Number of subjects: 7557
Study 31047955 — intervention group
Group type: COMPARATOR
Intervention: Classic CB definition
Number of subjects: 7557
Study 31048098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) - Epidiolex®
Number of subjects: 100
Study 31048330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg Q2W
Number of subjects: 51
Study 31048330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg Q2W, 240 mg Q2W, 360 mg once every 3 weeks
Number of subjects: 51
Study 31048330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg, 240 mg, 360 mg
Number of subjects: 51
Study 31048330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 51
Study 31048351 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative effect of smoking on disease burden
Number of subjects: 0
Study 31048351 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative effect of smoking on multimorbidity
Number of subjects: 0
Study 31048587 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) prediction model
Number of subjects: 603
Study 31048587 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 603
Study 31048587 — intervention group
Group type: COMPARATOR
Intervention: Logistic Regression (LR) model
Number of subjects: 603
Study 31049072 — intervention group
Group type: EXPERIMENTAL
Intervention: TF20 (HIFT program)
Number of subjects: 13
Study 31049072 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 13
Study 31049365 — intervention group
Group type: EXPERIMENTAL
Intervention: UC plus peer mentors (n = 54)
Number of subjects: 144
Study 31049365 — intervention group
Group type: EXPERIMENTAL
Intervention: UC plus cash incentives (n = 54)
Number of subjects: 144
Study 31049365 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) (n = 36)
Number of subjects: 144
Study 31049365 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups received 12 weeks of ledipasvir/sofosbuvir (LDV/SOF)
Number of subjects: 144
Study 31049365 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 144
Study 31049557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined non-invasive/invasive risk stratification approach with programmed ventricular stimulation (PVS) and implantable cardioverter-defibrillator (ICD) offered to inducible patients.
Number of subjects: 575
Study 31049557 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with at least one positive non-invasive risk factor (NIRF) referred for PVS.
Number of subjects: 575
Study 31049557 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for risk stratification.
Number of subjects: 575
Study 31049557 — intervention group
Group type: COMPARATOR
Intervention: Patients without NIRFs or with NIRFs but negative PVS.
Number of subjects: 575
Study 31049754 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) for monitoring regional cerebral oxygenation (rSO2)
Number of subjects: 0
Study 31049885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution (5, 10, or 20 mg/kg single dose on day 1; 10 mg/kg, 20 mg/kg, or 40 mg/kg total daily dose for days 4-10)
Number of subjects: 61
Study 31049885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution (40 mg/kg/day) with clobazam
Number of subjects: 61
Study 31050224 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial-shockable rhythms
Number of subjects: 4219
Study 31050224 — intervention group
Group type: COMPARATOR
Intervention: Converted-shockable rhythms
Number of subjects: 4219
Study 31050224 — intervention group
Group type: COMPARATOR
Intervention: Never-shockable rhythms
Number of subjects: 4219
Study 31050224 — intervention group
Group type: EXPERIMENTAL
Intervention: TOR criteria including unwitnessed events, no pre-hospital return of spontaneous circulation, and asystole in the emergency department
Number of subjects: 4219
Study 31050659 — intervention group
Group type: EXPERIMENTAL
Intervention: UCPPS
Number of subjects: 153
Study 31050659 — intervention group
Group type: COMPARATOR
Intervention: Mixed pain group
Number of subjects: 153
Study 31050659 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 153
Study 31050691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 452
Study 31050691 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 452
Study 31050868 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 0
Study 31050919 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 162
Study 31050919 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 162
Study 31051496 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 fatty acid supplementation
Number of subjects: 47
Study 31051503 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy foods (raw fruits, fish)
Number of subjects: 862
Study 31051503 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy foods (fried products, sodas, fatty sweet products, processed meats, ready-cooked meals, desserts)
Number of subjects: 862
Study 31051503 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits, fried products, ready-cooked meals, cheese
Number of subjects: 862
Study 31051503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 862
Study 31053093 — intervention group
Group type: EXPERIMENTAL
Intervention: CDI-DaySyms™ questionnaire
Number of subjects: 168
Study 31053093 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea Symptoms domain
Number of subjects: 168
Study 31053093 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal Symptoms domain
Number of subjects: 168
Study 31053093 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic/Other Symptoms domain
Number of subjects: 168
Study 31053102 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal microbiota transfer to neonates during the first 1000 days of life
Number of subjects: 0
Study 31053102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary information and environmental factors (gestational age, mode of delivery, maternal/infant diet, exposure to antibiotics)
Number of subjects: 0
Study 31053102 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific qPCR and 16S rRNA gene sequencing, SCFAs profile
Number of subjects: 0
Study 31053156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative Analogue Joint Involvement Scale (CAJIS)
Number of subjects: 114
Study 31053156 — intervention group
Group type: EXPERIMENTAL
Intervention: FOP-Physical Function Questionnaire (FOP-PFQ)
Number of subjects: 114
Study 31053156 — intervention group
Group type: EXPERIMENTAL
Intervention: HO volume measured by low-dose whole body CT
Number of subjects: 114
Study 31053174 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (PD-L1 blockade)
Number of subjects: 12
Study 31053210 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire
Number of subjects: 99
Study 31053210 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoring question
Number of subjects: 99
Study 31053538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 33
Study 31053601 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline peripheral blood NK-cell count (NKCC)
Number of subjects: 0
Study 31053957 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with preserved ejection fraction (HFpEF) patients
Number of subjects: 36
Study 31053957 — intervention group
Group type: COMPARATOR
Intervention: Patients without HFpEF (control group)
Number of subjects: 36
Study 31053957 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensated HFpEF patients
Number of subjects: 36
Study 31053957 — intervention group
Group type: EXPERIMENTAL
Intervention: RA-RV coupling in HFpEF patients
Number of subjects: 36
Study 31054013 — intervention group
Group type: EXPERIMENTAL
Intervention: IVC filter
Number of subjects: 1065
Study 31054013 — intervention group
Group type: COMPARATOR
Intervention: No IVC filter
Number of subjects: 1065
Study 31054035 — intervention group
Group type: EXPERIMENTAL
Intervention: MS Performance Test (MSPT)
Number of subjects: 1000
Study 31054118 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (0.01-5 mg/kg IV, 200-1200 mg IV, 0.25-1 mg/kg SC, 18-300 mg SC)
Number of subjects: 1899
Study 31055187 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective surgery
Number of subjects: 5063
Study 31055187 — intervention group
Group type: COMPARATOR
Intervention: Acute surgery
Number of subjects: 5063
Study 31055613 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-T cell therapy
Number of subjects: 53
Study 31055613 — intervention group
Group type: EXPERIMENTAL
Intervention: replacement and anticoagulant therapy
Number of subjects: 53
Study 31055977 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31056078 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary microvascular dysfunction
Number of subjects: 1
Study 31056369 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-insecure households
Number of subjects: 218
Study 31056369 — intervention group
Group type: COMPARATOR
Intervention: Food-secure households
Number of subjects: 218
Study 31056411 — intervention group
Group type: EXPERIMENTAL
Intervention: Current guideline-recommended ECG criteria for STEMI
Number of subjects: 2486
Study 31057004 — intervention group
Group type: EXPERIMENTAL
Intervention: Good adherence (taking medications ≥90% of the time as prescribed)
Number of subjects: 4001
Study 31057004 — intervention group
Group type: COMPARATOR
Intervention: No medications prescribed during follow-up
Number of subjects: 4001
Study 31057004 — intervention group
Group type: COMPARATOR
Intervention: Taking ≥1 medications
Number of subjects: 4001
Study 31057439 — intervention group
Group type: COMPARATOR
Intervention: Emotion reappraisal task
Number of subjects: 39
Study 31057439 — intervention group
Group type: COMPARATOR
Intervention: Baseline craving levels
Number of subjects: 39
Study 31057616 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary reverse mapping (ARM) using indocyanine green (ICG) for locating upper extremity lymphatics.
Number of subjects: 44
Study 31057686 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance MRI
Number of subjects: 1
Study 31057807 — intervention group
Group type: EXPERIMENTAL
Intervention: Carepartner and Constraint-Induced Therapy (CARE-CITE) with structured carepartner involvement during 30-h CIMT
Number of subjects: 48
Study 31057807 — intervention group
Group type: COMPARATOR
Intervention: Constraint-Induced Movement Therapy (CIMT) without structured carepartner involvement
Number of subjects: 48
Study 31057971 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Number of subjects: 47
Study 31058707 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater maternal prenatal cortisol reactivity in response to couple conflict discussion
Number of subjects: 123
Study 31058707 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater maternal prenatal cortisol reactivity
Number of subjects: 123
Study 31058707 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal prenatal depressive symptoms
Number of subjects: 123
Study 31058782 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics (AB+)
Number of subjects: 436
Study 31058782 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (AB-)
Number of subjects: 436
Study 31058782 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional antibiotic courses
Number of subjects: 436
Study 31058975 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ablation of pancreatic neuroendocrine neoplasms
Number of subjects: 0
Study 31059728 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation procedure
Number of subjects: 101
Study 31060047 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO group (43 patients)
Number of subjects: 361
Study 31060047 — intervention group
Group type: COMPARATOR
Intervention: Non-PFO group (273 patients)
Number of subjects: 361